The cut-off value for visfatin for the detection of subclinical atherosclerosis in patients using combination therapy with ACEI/ARB and CCB was 1.23 ng/mL, with a sensitivity of 86% and a specificity of 83% (the area under the curve was 0.881; 95% CI: 0.655–1.000; p = 0.022). Here, NAMPT is linked to atherosclerosis.